Coherus to Launch Cut-Rate Biosimilar Version of Humira with Help from Mark Cuban

Coherus BioSciences plans to sell a biosimilar version of Humira at an 85% discount in July with the help of Mark Cuban's Cost Plus Drug Company.
The Coherus biosimilar will have a list price of $995 for a two-autoinjector carton compared to Humira's $90,000 annual cost.
Patients will be able to get the Coherus biosimilar for about $13,000 per year compared to $90,000 for Humira.
The Coherus biosimilar, called Yusimry, will be available through Mark Cuban's Cost Plus Drug Company for $569 plus fees.
Coherus will be one of several companies launching Humira biosimilars in the U.S., providing a cheaper alternative to AbbVie's blockbuster biologic drug used by 300,000 patients annually.